BFS
KNSA icon

Bare Financial Services’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bare Financial Services’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02K Hold
16
– – ﹤0.01% 1374
2026
Q1 		$770 Buy
+16
New +$709 ﹤0.01% 1363

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Bare Financial Services's KNSA Position: Q2 2026 in Review

Bare Financial Services held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 16 shares worth $1.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Bare Financial Services first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Bare Financial Services held 16 shares of Kiniksa Pharmaceuticals worth $1.02K as of Q2 2026.
  • Bare Financial Services left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1374 holding.
  • Bare Financial Services first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.